Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Rafarma Pharmaceuticals, Inc.    RAFA

RAFARMA PHARMACEUTICALS, INC.

(RAFA)
SummaryQuotesChartsNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Rafarma Pharmaceuticals : Auditing Firm L J Soldinger Associates Retained for Rafarma Biocogency Merger

11/04/2020 | 09:02am EST

Nicosia, Cyprus, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that the elite Chicago auditing firm LJ Soldinger Associates (https://www.soldinger.com/) has been retained to provide auditing services for the resulting Rafarma group of companies from the Biocogency/Rafarma merger.

Ilya Spurov, Chairman of Rafarma, commented: “The reputation of LJ Soldinger Associates gives us confidence that our transition will be smooth, professional and efficient.”

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For more information contact:
RAFARMA
(307) 429-2029


LOGO.png

Source: RAFARMA PHARMACEUTICALS INC

2020 GlobeNewswire, Inc., source Press Releases

All news about RAFARMA PHARMACEUTICALS, INC.
2020Rafarma Merger Company Bebig Approved For Production And Sale Of Yttrium-90 F..
GL
2020Rafarma Inks Joint Venture Agreement with Vaccines Lab SDN BHD of Malaysia
GL
2020RAFARMA PHARMACEUTICALS : Letter To Shareholders from Chairman Ilya Shpurov
AQ
2020Letter To Shareholders from Chairman Ilya Shpurov
GL
2020RAFARMA PHARMACEUTICALS : Auditing Firm L J Soldinger Associates Retained for Ra..
AQ
2020Auditing Firm L J Soldinger Associates Retained for Rafarma Biocogency Merger
GL
2020RAFARMA PHARMACEUTICALS : Closes Biocogency Merger
AQ
2020Rafarma Closes Biocogency Merger
GL
2020RAFARMA PHARMACEUTICALS : Approves Issuance of Majority of Voting Shares to Boar..
AQ
2020Rafarma Approves Issuance of Majority of Voting Shares to Board Chairman Ilya..
GL
More news
Chart RAFARMA PHARMACEUTICALS, INC.
Duration : Period :
Rafarma Pharmaceuticals, Inc. Technical Analysis Chart | RAFA | US75062C1009 | MarketScreener
Managers and Directors
NameTitle
Vladimir G. Dolgolenko President & Chief Executive Officer
Ilya Shpurov Chairman